At what age does retinoblastoma typically occur in children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 22, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Onset of Retinoblastoma

Retinoblastoma typically occurs in early childhood, with risks beginning in early infancy and approximately 80% of cases diagnosed before age 4 years, with a median age at diagnosis of 2 years. 1, 2

Age Distribution and Timing

  • Hereditary retinoblastoma risks begin in early infancy, requiring ophthalmologic examination promptly after birth (ideally within 24 hours) for at-risk infants to maximize visual outcomes through early tumor detection 1

  • Bilateral retinoblastoma presents earlier than unilateral disease, with bilateral tumors typically appearing at 18-24 months compared to unilateral cases at approximately 36 months 3

  • Over 90% of retinoblastoma cases present before age 5 years, making this the critical surveillance window 4

  • Neonatal retinoblastoma can be diagnosed in the first month of life, with family history being the most common reason for detection (67% of cases) rather than leukocoria (13%) in this age group 5

Age-Related Clinical Patterns

  • Young age at onset is a predictor of hereditary disease in children with unilateral unifocal retinoblastoma, along with macular tumor location 1

  • Children diagnosed at ≤12 months have a higher proportion of RB1 gene pathogenic variants compared to those diagnosed after 12 months (P=0.034) 6

  • Retinoblastoma in children older than 5 years is uncommon but does occur, representing only 16 out of 453 cases (3.5%) in one series, with a median age at diagnosis of 73.7 months (range 65-144 months) 2

  • Bilateral or trilateral retinoblastoma in children aged 3-5 years warrants RB1 gene testing even without family history, as there remains a significant proportion of pathogenic variants in this age group 6

Clinical Implications for Surveillance

  • The yearly incidence of retinoblastoma in children under 15 years is 0.00036%-0.00041%, making it a rare but critical diagnosis to identify early 1

  • Diagnosis is often delayed in older children (>5 years) due to low clinical suspicion at this age, with a mean time between first symptoms and diagnosis of 9.6 months 2

  • Adult-onset retinoblastoma (>20 years) is extremely rare, with only 45 cases reported in the literature as of 2016, though increasing awareness has led to more recent reports 7

Common Pitfalls

  • Do not dismiss the possibility of retinoblastoma based solely on age, as cases can occur beyond the typical 0-5 year window, though with decreasing frequency 2, 7

  • Family history may be absent in hereditary cases due to de novo germline RB1 pathogenic variants or variants with reduced penetrance, so germline testing should be performed for all children with retinoblastoma regardless of laterality or family history 1

  • Delayed diagnosis in older children leads to more advanced disease at presentation, with most cases in children >5 years diagnosed at advanced stages (Reese V or extraocular disease) 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Retinoblastoma in children older than 5 years of age.

Pediatric blood & cancer, 2007

Guideline

Classification and Prognosis of Retinoblastoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

(Neonatal) retinoblastoma in the first month of life.

Archives of ophthalmology (Chicago, Ill. : 1960), 2002

Research

Adult onset retinoblastoma.

Indian journal of ophthalmology, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.